Announced
Completed
Financials
Tags
cancer treatment
treatment development
biotechnology
Biotechnology
United States
Public
Acquisition
Completed
Friendly
Single Bidder
Synopsis
Seattle Genetics Inc. and Cascadian Therapeutics Inc. announced the signing of a definitive merger agreement under which Seattle Genetics has agreed to acquire Cascadian Therapeutics. Under the terms of the agreement, Seattle Genetics will pay $10.00 per share in cash, or approximately $614 million. The transaction was unanimously approved by the Boards of Directors of both companies. The transaction is anticipated to close in the first quarter of 2018.
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.